View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEpigenomics 과거 순이익 실적과거 기준 점검 0/6Epigenomics은 연평균 7.7%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 5.4%의 비율로 증가했습니다.핵심 정보7.71%순이익 성장률42.41%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률5.41%자기자본이익률n/a순이익률-1,315.79%다음 순이익 업데이트30 Sep 2024최근 과거 실적 업데이트Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.공시 • Nov 09+ 4 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.모든 업데이트 보기Recent updatesNew Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).Price Target Changed • Dec 18Price target increased by 227% to €52.65Up from €16.13, the current price target is an average from 2 analysts. New target price is 2,671% above last closing price of €1.90. Stock is down 74% over the past year. The company is forecast to post a net loss per share of €8.53 next year compared to a net loss per share of €14.78 last year.Major Estimate Revision • Dec 14Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €900.0k to €800.0k. Forecast losses increased from -€7.35 to -€8.53 per share. Biotechs industry in Germany expected to see average net income growth of 23% next year. Consensus price target up from €15.12 to €15.80. Share price fell 22% to €2.00 over the past week.Major Estimate Revision • Dec 13Consensus revenue estimates decrease by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €900.0k to €800.0k. EPS estimate unchanged from -€8.60 per share at last update. Biotechs industry in Germany expected to see average net income growth of 23% next year. Consensus price target broadly unchanged at €16.15. Share price fell 5.7% to €2.48 over the past week.공시 • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.공시 • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.Major Estimate Revision • Aug 17Consensus revenue estimates increase by 139%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from €380.0k to €900.0k. Forecast losses expected to reduce from -€1.63 to -€1.47 per share. Biotechs industry in Germany expected to see average net income growth of 4.3% next year. Consensus price target down from €6.00 to €3.23. Share price fell 7.1% to €0.65 over the past week.Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.Buying Opportunity • Aug 02Now 30% undervaluedOver the last 90 days, the stock is up 6.9%. The fair value is estimated to be €1.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.공시 • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.Buying Opportunity • Jul 06Now 23% undervaluedOver the last 90 days, the stock is up 7.9%. The fair value is estimated to be €0.99, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.분석 기사 • Jul 02A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)Key Insights Using the 2 Stage Free Cash Flow to Equity, Epigenomics fair value estimate is €0.99 With €0.88 share...공시 • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.Price Target Changed • Jun 02Price target increased by 9.1% to €6.00Up from €5.50, the current price target is provided by 1 analyst. New target price is 900% above last closing price of €0.60. Stock is down 69% over the past year. The company is forecast to post a net loss per share of €1.63 next year compared to a net loss per share of €2.96 last year.Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.공시 • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.Price Target Changed • Dec 22Price target increased to €1.17Up from €1.07, the current price target is an average from 2 analysts. New target price is 207% above last closing price of €0.38. Stock is down 35% over the past year. The company is forecast to post a net loss per share of €0.71 next year compared to a net loss per share of €0.22 last year.Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -€0.99 to -€0.74 per share. Revenue forecast unchanged from €544.5k at last update. Biotechs industry in Germany expected to see average net income growth of 2.6% next year. Consensus price target of €1.07 unchanged from last update. Share price rose 6.4% to €0.35 over the past week.Breakeven Date Change • Nov 16No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.공시 • Nov 09+ 4 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023공시 • Sep 20Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022Epigenomics AG reaffirmed revenue guidance for the full year 2022. For the period, the company revenue forecast remains unchanged between EUR 0.3 million to EUR 0.8 million.Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.Price Target Changed • Aug 12Price target decreased to €0.98Down from €1.07, the current price target is an average from 2 analysts. New target price is 97% above last closing price of €0.50. Stock is down 53% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.공시 • Aug 12Epigenomics AG Confirms Outlook for Fiscal Year 2022Epigenomics AG confirmed outlook for fiscal year 2022 and continues to expect revenue within the range of EUR 0.3 million to EUR 0.8 million.Price Target Changed • Jun 01Price target increased to €1.07Up from €0.95, the current price target is an average from 2 analysts. New target price is 119% above last closing price of €0.49. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.17 loss per share. Revenue: €115.0k (up 8.5% from 1Q 2021). Net loss: €2.66m (loss widened 121% from 1Q 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 91% compared to a 36% growth forecast for the industry in Germany.공시 • May 12Epigenomics AG Confirms Earnings Guidance for the Year 2022Epigenomics AG confirmed earnings guidance for the year 2022. For the year, The company expects revenue within the range of EUR 0.3 million to EUR 0.8 million. If Medicare reimbursement is indeed achieved via legislation in 2022, the Company is likely to amend the revenue forecast.Price Target Changed • Apr 27Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 96% above last closing price of €0.48. Stock is down 61% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Breakeven Date Change • Apr 05No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.Price Target Changed • Mar 28Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 76% above last closing price of €0.54. Stock is down 78% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.23 (vs €0.47 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €5.80m (up €5.58m from 3Q 2020). Net income: €2.84m (up €5.59m from 3Q 2020). Profit margin: 49% (up from net loss in 3Q 2020).Price Target Changed • Nov 11Price target decreased to €1.14Down from €1.49, the current price target is an average from 2 analysts. New target price is 30% above last closing price of €0.88. Stock is down 76% over the past year. The company is forecast to post a net loss per share of €0.94 next year compared to a net loss per share of €2.02 last year.공시 • Aug 18New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million.New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million on August 17, 2021. The gross proceeds of $6.7 million will be paid as; $4.7 million at closing and the remaining is payable within 90 days upon providing verification of sample integrity and documentation.Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.21 loss per share (vs €0.57 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: €117.0k (up 41% from 2Q 2020). Net loss: €2.33m (loss narrowed 31% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Price Target Changed • Jul 12Price target decreased to €1.44Down from €6.37, the current price target is an average from 3 analysts. New target price is 10% above last closing price of €1.30. Stock is down 91% over the past year.분석 기사 • Jun 12We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Major Estimate Revision • Jun 03Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€1.41 to -€1.19 per share. Revenue forecast steady at €597.7k. Biotechs industry in Germany expected to see average net income growth of 0.7% next year. Consensus price target of €8.75 unchanged from last update. Share price rose 25% to €1.83 over the past week.Breakeven Date Change • May 21Forecast to breakeven in 2023The 2 analysts covering Epigenomics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 25% per year to 2022. The company is expected to make a profit of €4.48m in 2023. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Reported Earnings • May 14First quarter 2021 earnings released: €0.20 loss per share (vs €0.55 loss in 1Q 2020)First quarter 2021 results: Net loss: €1.20m (loss narrowed 60% from 1Q 2020).공시 • May 12Epigenomics AG Announces Earnings Guidance for the Year 2021Epigenomics AG announced earnings guidance for the year 2021. For the year, the company its outlook continues to expect revenue within the range of EUR 0.4 million to EUR 1.0 million.Major Estimate Revision • Apr 29Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €595.4k to €1.00m. EPS estimate reaffirmed at -€1.41 per share. Biotechs industry in Germany expected to see average net income growth of 0.7% next year. Consensus price target of €14.97 unchanged from last update. Share price fell 18% to €1.24 over the past week.Major Estimate Revision • Mar 28Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €7.55m to €10.8m. EPS estimate fell from -€0.95 to -€1.36 per share. Biotechs industry in Germany expected to see average net income growth of 2.3% next year. Consensus price target up from €16.27 to €21.20. Share price rose 18% to €2.65 over the past week.공시 • Mar 27Epigenomics AG Provides Earnings Guidance for the Year 2021Epigenomics AG provided earnings guidance for the year 2021. For 2021 financial outlook is a revenue range of EUR 400,000 to EUR 1 million.Is New 90 Day High Low • Mar 03New 90-day low: €2.30The company is down 37% from its price of €3.66 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.09 per share.분석 기사 • Feb 15When Will Epigenomics AG (ETR:ECX) Breakeven?We feel now is a pretty good time to analyse Epigenomics AG's ( ETR:ECX ) business as it appears the company may be on...Price Target Changed • Feb 13Price target lowered to €16.27Down from €23.73, the current price target is an average from 3 analysts. The new target price is 538% above the current share price of €2.55. As of last close, the stock is down 77% over the past year.공시 • Jan 29Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021Epigenomics AG announced that Dr. Jorge Garces, President and Chief Scientific Officer is resigning as an Executive Board member effective January 31, 2021. Dr. Garces will transition to a company Advisor role to assist the company through the end of 2021 with execution of strategic alternatives.공시 • Jan 21Epigenomics Ag Announces the U.S. Centers for Medicare & Medicaid Services (CMS) Have Issued A Negative Reimbursement Decision in Connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' Blood Test for Colorectal Cancer ScreeningEpigenomics AG announced that the U.S. Centers for Medicare & Medicaid Services (CMS) have issued a negative reimbursement decision in connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' blood test for colorectal cancer screening. The Company is currently evaluating options for an appeal, litigation and/or other alternatives to achieve Medicare coverage.공시 • Dec 19+ 4 more updatesEpigenomics AG to Report Fiscal Year 2020 Results on Mar 25, 2021Epigenomics AG announced that they will report fiscal year 2020 results on Mar 25, 2021공시 • Nov 13Epigenomics AG Pulls Revenue Guidance for the Year 2020 Due to Covid-19Epigenomics AG announced that due to the continued uncertainty surrounding the effects of Covid-19, Epigenomics AG, like many publicly traded companies and as already explained in the first half 2020 report, has pulled its revenue guidance for 2020.공시 • Oct 18Epigenomics AG announces the U.S. Centers for Medicare & Medicaid Services have issued a negative reimbursement proposal in connection with the National Coverage Determination of Epi proColon, Epigenomics' blood test for colorectal cancer screeningEpigenomics AG announced that the U.S. Centers for Medicare & Medicaid Services (CMS) have issued a negative reimbursement proposal in connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' blood test for colorectal cancer screening. The proposed NCD is preliminary. According to the statutes, a 30-day public comment period will now begin, which will be used to further convince CMS of the benefits of Epi proColon in the fight against colorectal cancer. The public response during the initial public comment period at the beginning of the NCD was overwhelmingly positive. Following the comment period, CMS will publish their final decision within 60 days. If the final decision is also negative, the Company will take the opportunity to appeal the decision.공시 • Aug 24Epigenomics Ag Pulls Its Revenue Guidance for 2020Epigenomics AG announced that the company is pulling its revenue guidance for 2020.매출 및 비용 세부 내역Epigenomics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XTRA:ECX 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 230-44030 Sep 231-183-430 Jun 230-1610531 Mar 231-159631 Dec 221-173030 Sep 221-77630 Jun 226-38531 Mar 226-48431 Dec 216-28330 Sep 216-38230 Jun 211-96231 Mar 211-107331 Dec 201-127430 Sep 201-168530 Jun 201-168631 Mar 201-179731 Dec 191-179730 Sep 191-1410830 Jun 191-1410731 Mar 192-129631 Dec 182-139630 Sep 182-118630 Jun 182-107531 Mar 182-118531 Dec 172-108430 Sep 173-98430 Jun 173-1010431 Mar 174-99431 Dec 164-1110530 Sep 163-119530 Jun 163-119531 Mar 162-107631 Dec 152-95630 Sep 152-116730 Jun 152-105631 Mar 151-105631 Dec 142-95530 Sep 142-85430 Jun 142-85431 Mar 142-85531 Dec 132-75430 Sep 131-845양질의 수익: ECX 은(는) 현재 수익성이 없습니다.이익 마진 증가: ECX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ECX는 수익성이 없지만 지난 5년 동안 연평균 7.7%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ECX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ECX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(45%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ECX의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/07/10 12:26종가2024/07/10 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Epigenomics AG는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hans Bjorn BostromEdison Investment ResearchSimon ScholesFirst Berlin Equity Research GmbHBryan BrokmeierMaxim Group2명의 분석가 더 보기
Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.
공시 • Nov 09+ 4 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023
Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding).
Price Target Changed • Dec 18Price target increased by 227% to €52.65Up from €16.13, the current price target is an average from 2 analysts. New target price is 2,671% above last closing price of €1.90. Stock is down 74% over the past year. The company is forecast to post a net loss per share of €8.53 next year compared to a net loss per share of €14.78 last year.
Major Estimate Revision • Dec 14Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €900.0k to €800.0k. Forecast losses increased from -€7.35 to -€8.53 per share. Biotechs industry in Germany expected to see average net income growth of 23% next year. Consensus price target up from €15.12 to €15.80. Share price fell 22% to €2.00 over the past week.
Major Estimate Revision • Dec 13Consensus revenue estimates decrease by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €900.0k to €800.0k. EPS estimate unchanged from -€8.60 per share at last update. Biotechs industry in Germany expected to see average net income growth of 23% next year. Consensus price target broadly unchanged at €16.15. Share price fell 5.7% to €2.48 over the past week.
공시 • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.
공시 • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.
Major Estimate Revision • Aug 17Consensus revenue estimates increase by 139%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from €380.0k to €900.0k. Forecast losses expected to reduce from -€1.63 to -€1.47 per share. Biotechs industry in Germany expected to see average net income growth of 4.3% next year. Consensus price target down from €6.00 to €3.23. Share price fell 7.1% to €0.65 over the past week.
Reported Earnings • Aug 13Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022)Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
Buying Opportunity • Aug 02Now 30% undervaluedOver the last 90 days, the stock is up 6.9%. The fair value is estimated to be €1.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.
공시 • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.
Buying Opportunity • Jul 06Now 23% undervaluedOver the last 90 days, the stock is up 7.9%. The fair value is estimated to be €0.99, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years.
분석 기사 • Jul 02A Look At The Intrinsic Value Of Epigenomics AG (ETR:ECX1)Key Insights Using the 2 Stage Free Cash Flow to Equity, Epigenomics fair value estimate is €0.99 With €0.88 share...
공시 • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.
Price Target Changed • Jun 02Price target increased by 9.1% to €6.00Up from €5.50, the current price target is provided by 1 analyst. New target price is 900% above last closing price of €0.60. Stock is down 69% over the past year. The company is forecast to post a net loss per share of €1.63 next year compared to a net loss per share of €2.96 last year.
Reported Earnings • Jun 01First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022)First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany.
공시 • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.
Reported Earnings • May 01Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021)Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.
Price Target Changed • Dec 22Price target increased to €1.17Up from €1.07, the current price target is an average from 2 analysts. New target price is 207% above last closing price of €0.38. Stock is down 35% over the past year. The company is forecast to post a net loss per share of €0.71 next year compared to a net loss per share of €0.22 last year.
Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -€0.99 to -€0.74 per share. Revenue forecast unchanged from €544.5k at last update. Biotechs industry in Germany expected to see average net income growth of 2.6% next year. Consensus price target of €1.07 unchanged from last update. Share price rose 6.4% to €0.35 over the past week.
Breakeven Date Change • Nov 16No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany.
공시 • Nov 09+ 4 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023
공시 • Sep 20Epigenomics Ag Reaffirms Revenue Guidance for the Full Year 2022Epigenomics AG reaffirmed revenue guidance for the full year 2022. For the period, the company revenue forecast remains unchanged between EUR 0.3 million to EUR 0.8 million.
Reported Earnings • Aug 15Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany.
Price Target Changed • Aug 12Price target decreased to €0.98Down from €1.07, the current price target is an average from 2 analysts. New target price is 97% above last closing price of €0.50. Stock is down 53% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.
공시 • Aug 12Epigenomics AG Confirms Outlook for Fiscal Year 2022Epigenomics AG confirmed outlook for fiscal year 2022 and continues to expect revenue within the range of EUR 0.3 million to EUR 0.8 million.
Price Target Changed • Jun 01Price target increased to €1.07Up from €0.95, the current price target is an average from 2 analysts. New target price is 119% above last closing price of €0.49. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year.
Reported Earnings • May 14First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.17 loss per share. Revenue: €115.0k (up 8.5% from 1Q 2021). Net loss: €2.66m (loss widened 121% from 1Q 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 91% compared to a 36% growth forecast for the industry in Germany.
공시 • May 12Epigenomics AG Confirms Earnings Guidance for the Year 2022Epigenomics AG confirmed earnings guidance for the year 2022. For the year, The company expects revenue within the range of EUR 0.3 million to EUR 0.8 million. If Medicare reimbursement is indeed achieved via legislation in 2022, the Company is likely to amend the revenue forecast.
Price Target Changed • Apr 27Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 96% above last closing price of €0.48. Stock is down 61% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Breakeven Date Change • Apr 05No longer forecast to breakevenThe 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024.
Price Target Changed • Mar 28Price target decreased to €0.95Down from €1.14, the current price target is an average from 2 analysts. New target price is 76% above last closing price of €0.54. Stock is down 78% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.23 (vs €0.47 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €5.80m (up €5.58m from 3Q 2020). Net income: €2.84m (up €5.59m from 3Q 2020). Profit margin: 49% (up from net loss in 3Q 2020).
Price Target Changed • Nov 11Price target decreased to €1.14Down from €1.49, the current price target is an average from 2 analysts. New target price is 30% above last closing price of €0.88. Stock is down 76% over the past year. The company is forecast to post a net loss per share of €0.94 next year compared to a net loss per share of €2.02 last year.
공시 • Aug 18New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million.New Horizon Health Limited (SEHK:6606) entered into an agreement to acquire certain non-essential biological samples from Epigenomics AG (XTRA:ECX) for $6.7 million on August 17, 2021. The gross proceeds of $6.7 million will be paid as; $4.7 million at closing and the remaining is payable within 90 days upon providing verification of sample integrity and documentation.
Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.21 loss per share (vs €0.57 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: €117.0k (up 41% from 2Q 2020). Net loss: €2.33m (loss narrowed 31% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Price Target Changed • Jul 12Price target decreased to €1.44Down from €6.37, the current price target is an average from 3 analysts. New target price is 10% above last closing price of €1.30. Stock is down 91% over the past year.
분석 기사 • Jun 12We're Keeping An Eye On Epigenomics' (ETR:ECX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Major Estimate Revision • Jun 03Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -€1.41 to -€1.19 per share. Revenue forecast steady at €597.7k. Biotechs industry in Germany expected to see average net income growth of 0.7% next year. Consensus price target of €8.75 unchanged from last update. Share price rose 25% to €1.83 over the past week.
Breakeven Date Change • May 21Forecast to breakeven in 2023The 2 analysts covering Epigenomics expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 25% per year to 2022. The company is expected to make a profit of €4.48m in 2023. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Reported Earnings • May 14First quarter 2021 earnings released: €0.20 loss per share (vs €0.55 loss in 1Q 2020)First quarter 2021 results: Net loss: €1.20m (loss narrowed 60% from 1Q 2020).
공시 • May 12Epigenomics AG Announces Earnings Guidance for the Year 2021Epigenomics AG announced earnings guidance for the year 2021. For the year, the company its outlook continues to expect revenue within the range of EUR 0.4 million to EUR 1.0 million.
Major Estimate Revision • Apr 29Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €595.4k to €1.00m. EPS estimate reaffirmed at -€1.41 per share. Biotechs industry in Germany expected to see average net income growth of 0.7% next year. Consensus price target of €14.97 unchanged from last update. Share price fell 18% to €1.24 over the past week.
Major Estimate Revision • Mar 28Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €7.55m to €10.8m. EPS estimate fell from -€0.95 to -€1.36 per share. Biotechs industry in Germany expected to see average net income growth of 2.3% next year. Consensus price target up from €16.27 to €21.20. Share price rose 18% to €2.65 over the past week.
공시 • Mar 27Epigenomics AG Provides Earnings Guidance for the Year 2021Epigenomics AG provided earnings guidance for the year 2021. For 2021 financial outlook is a revenue range of EUR 400,000 to EUR 1 million.
Is New 90 Day High Low • Mar 03New 90-day low: €2.30The company is down 37% from its price of €3.66 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.09 per share.
분석 기사 • Feb 15When Will Epigenomics AG (ETR:ECX) Breakeven?We feel now is a pretty good time to analyse Epigenomics AG's ( ETR:ECX ) business as it appears the company may be on...
Price Target Changed • Feb 13Price target lowered to €16.27Down from €23.73, the current price target is an average from 3 analysts. The new target price is 538% above the current share price of €2.55. As of last close, the stock is down 77% over the past year.
공시 • Jan 29Epigenomics AG Announces Resignation of Jorge Garces as Executive Board Member Effective January 31, 2021Epigenomics AG announced that Dr. Jorge Garces, President and Chief Scientific Officer is resigning as an Executive Board member effective January 31, 2021. Dr. Garces will transition to a company Advisor role to assist the company through the end of 2021 with execution of strategic alternatives.
공시 • Jan 21Epigenomics Ag Announces the U.S. Centers for Medicare & Medicaid Services (CMS) Have Issued A Negative Reimbursement Decision in Connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' Blood Test for Colorectal Cancer ScreeningEpigenomics AG announced that the U.S. Centers for Medicare & Medicaid Services (CMS) have issued a negative reimbursement decision in connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' blood test for colorectal cancer screening. The Company is currently evaluating options for an appeal, litigation and/or other alternatives to achieve Medicare coverage.
공시 • Dec 19+ 4 more updatesEpigenomics AG to Report Fiscal Year 2020 Results on Mar 25, 2021Epigenomics AG announced that they will report fiscal year 2020 results on Mar 25, 2021
공시 • Nov 13Epigenomics AG Pulls Revenue Guidance for the Year 2020 Due to Covid-19Epigenomics AG announced that due to the continued uncertainty surrounding the effects of Covid-19, Epigenomics AG, like many publicly traded companies and as already explained in the first half 2020 report, has pulled its revenue guidance for 2020.
공시 • Oct 18Epigenomics AG announces the U.S. Centers for Medicare & Medicaid Services have issued a negative reimbursement proposal in connection with the National Coverage Determination of Epi proColon, Epigenomics' blood test for colorectal cancer screeningEpigenomics AG announced that the U.S. Centers for Medicare & Medicaid Services (CMS) have issued a negative reimbursement proposal in connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics' blood test for colorectal cancer screening. The proposed NCD is preliminary. According to the statutes, a 30-day public comment period will now begin, which will be used to further convince CMS of the benefits of Epi proColon in the fight against colorectal cancer. The public response during the initial public comment period at the beginning of the NCD was overwhelmingly positive. Following the comment period, CMS will publish their final decision within 60 days. If the final decision is also negative, the Company will take the opportunity to appeal the decision.
공시 • Aug 24Epigenomics Ag Pulls Its Revenue Guidance for 2020Epigenomics AG announced that the company is pulling its revenue guidance for 2020.